A South Korean life sciences company plans to open a genetic testing lab in North Austin, a move that could create up to 200 ...

New peptide research blend shows promise as a game-changer in the fitness space BURTON, MI, UNITED STATES, January 19, ...

They work inside integrated development environments (IDEs), where code, documentation, testing, version history and ...

The biopharmaceutical company may start to offer two cancer therapies and an additional HIV treatment option this year.

Gilead Sciences, Inc. (NASDAQ:GILD) is one of the best medical research stocks to buy according to hedge funds. On February 11, BofA lifted the price target on Gilead Sciences, Inc. (NASDAQ:GILD) to ...

The salmon-flavored treat helps with pain management.

Students, young professionals, and industry leaders invited to explore emerging GIS trends and network with innovators ...

Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the fourth quarter and full year 2025.

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people.

Dr. Cindi Love, Executive Director of Out for Undergrad, emphasized the significance of Valladares’ appointment: ...

Gilead's revenue is anchored by Biktarvy, protected by exclusivity through 2036, reducing near-term patent cliff risk vs. peers. Learn more about GILD stock here.

Q4 2025 Earnings Call February 10, 2026 4:30 PM ESTCompany ParticipantsJacquie Ross - Senior Vice President of Treasury ...